




Transatlantic Taskforce on Antimicrobial Resistance (TATFAR)

Antimicrobial resistance (AMR) is a public health problem of increasing magnitude and importance recognized by the European Union (EU) and the United States (U.S.).



Overview

- TATFAR was created in 2009 in response to an EU-U.S. presidential summit declaration to address urgent AMR issues
- The Taskforce consists of members from multiple EU and U.S. government agencies
- TATFAR creates enhanced cooperation and communication between the members

3 Key Focus Areas



Appropriate therapeutic use of antimicrobial drugs in medical and veterinary communities



Prevention of healthcare- and community-associated drug-resistant infections



Strategies for improving the pipeline of new antimicrobial drugs



Conducted point prevalence surveys to address gaps in AMR surveillance, generating national estimates of the burden of healthcare-associated infections in the EU and U.S.



Organized opportunities for scientific groups to discuss development of new diagnostic tests and coordination of similar clinical trials



Collaborated to support drug development programs to satisfy regulatory requirements in both the EU and U.S.



Hosted regular bilateral meetings to discuss guidelines and recommendations of antimicrobial drugs for use in veterinary medicine



Convened a multidisciplinary expert panel to develop common structure and process indicators for hospital antimicrobial stewardship programs to standardize use and prescribing practices internationally

TATFAR Successes

TATFAR Moving Forward

With successful collaboration to date, TATFAR's mandate continues to be renewed.

Future TATFAR actions are expected to include activities like:



Working toward harmonization of interpretive criteria for AMR surveillance



Collaborating on common systems for reporting and analyzing resistance patterns for urgent and serious pathogens



Continuing to address key knowledge gaps in understanding the impact of antimicrobial use in animals on the risk to man from antimicrobial resistance



Expanding AMR expertise with new Taskforce members, Canada and Norway